Portal de investigación
Targeted Delivery of the Pan-Inflammasome Inhibitor MM01 as an Alternative Approach to Acute Lung Injury Therapy.
Fecha de publicación:
Fecha Ahead of Print:
Autores de CIPF
Participantes ajenos a CIPF
- Garrido E
Grupos de Investigación
Abstract
Acute lung injury (ALI) is a severe pulmonary disorder responsible for high percentage of mortality and morbidity in intensive care unit patients. Current treatments are ineffective, so the development of efficient and specific therapies is an unmet medical need. The activation of NLPR3 inflammasome during ALI produces the release of proinflammatory factors and pyroptosis, a proinflammatory form of cell death that contributes to lung damage spreading. Herein, it is demonstrated that modulating inflammasome activation through inhibition of ASC oligomerization by the recently described MM01 compound can be an alternative pharmacotherapy against ALI. Besides, the added efficacy of using a drug delivery nanosystem designed to target the inflamed lungs is determined. The MM01 drug is incorporated into mesoporous silica nanoparticles capped with a peptide (TNFR-MM01-MSNs) to target tumor necrosis factor receptor-1 (TNFR-1) to proinflammatory macrophages. The prepared nanoparticles can deliver the cargo in a controlled manner after the preferential uptake by proinflammatory macrophages and exhibit anti-inflammatory activity. Finally, the therapeutic effect of MM01 free or nanoparticulated to inhibit inflammatory response and lung injury is successfully demonstrated in lipopolysaccharide-mouse model of ALI. The results suggest the potential of pan-inflammasome inhibitors as candidates for ALI therapy and the use of nanoparticles for targeted lung delivery.
Datos de la publicación
- ISSN/ISSNe:
- 2192-2640, 2192-2659
- Tipo:
- Article
- Páginas:
- -
- PubMed:
- 37515468
Advanced Healthcare Materials John Wiley and Sons Ltd
Citas Recibidas en Web of Science: 9
Documentos
- No hay documentos
Filiaciones
Keywords
- MM01, acute lung injury, mesoporous silica nanoparticles, targeted-lung delivery
Proyectos asociados
El Eje IRS2/FGF7 en el Hígado
Investigador Principal: LUKE ADAM NOON WELSH
MINISTERIO DE CIENCIA, INNOVACION Y UNIVERSIDADES . 2021
El interactoma de membrana de las proteínas de la familia Bcl-2 como diana antitumoral
Investigador Principal: MARIA MAR ORZÁEZ CALATAYUD
MINISTERIO DE CIENCIA, INNOVACION Y UNIVERSIDADES . 2021
VALORIZATION OF A FIRST-IN-CLASS MCL-1 INHIBITOR
Investigador Principal: MARIA MAR ORZÁEZ CALATAYUD
MINISTERIO DE CIENCIA, INNOVACION Y UNIVERSIDADES . 2021
Nanoplataforma Polipeptídica Multimodal de Precisión para el Tratamiento y Monitorización de Tumores Metastásicos. Colab I-36, I-12, I-63, servicio citómica, uji y gva (Esther Roselló)
Investigador Principal: MARIA JESUS VICENT DOCON
CONSELLERIA DE EDUCACION . 2022
THE FUTURE OF BIOMEDICAL RESEARCH (FBR) CIPF LECTURE SERIES
Investigador Principal: FRANCISCO GARCÍA GARCÍA
2023
Sinergias en descubrimiento de fármacos en España. ES-OPENSCREEN_2
Investigador Principal: MARIA JESUS VICENT DOCON
MINISTERIO DE CIENCIA, INNOVACION Y UNIVERSIDADES . 2023
Red de investigación en inflammasoma y piroptosis en enfermedades crónicas y cáncer (INFLAMMASOMA)
Investigador Principal: MARIA MAR ORZÁEZ CALATAYUD
MINISTERIO DE CIENCIA, INNOVACION Y UNIVERSIDADES . 2023